Shopping Cart
Remove All
Your shopping cart is currently empty
Futuximab is a chimeric monoclonal antibody targeting EGFR, commonly used in combination with zatuximab to form Sym004. Sym004 targets non-overlapping epitopes on EGFR, exhibiting antitumour activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $745 | - | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,770 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
| Description | Futuximab is a chimeric monoclonal antibody targeting EGFR, commonly used in combination with zatuximab to form Sym004. Sym004 targets non-overlapping epitopes on EGFR, exhibiting antitumour activity. |
| In vitro | In NR6M cells, Futuximab (20 µg/mL, 24-48 hours) induced EGFRvIII internalization and caused a slight decrease in EGFRvIII levels [1]. |
| In vivo | In the EGFRwt-expressing parazacco spilurus subsp. spilurus xenograft model, Futuximab (50 mg/kg, intraperitoneal injection, twice weekly for 5 consecutive weeks) demonstrated significant antitumor activity [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 1310460-85-5 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.